Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria



Liu, Yingjun, Pertinez, Henry, Ortega-Muro, Fatima, Alameda-Martin, Laura, Harrison, Thomas, Davies, Geraint ORCID: 0000-0002-3819-490X, Coates, Anthony and Hu, Yanmin
(2018) Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73 (3). pp. 724-731.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Objectives</h4>Although high-dose rifampicin holds promise for improving tuberculosis disease control by eradication of persistent bacteria, the optimal dose of rifampicin that kills persistent bacteria and shortens the treatment duration is unknown.<h4>Methods</h4>The Cornell mouse model was used to test the efficacy of rifampicin at elevated doses combined with isoniazid and pyrazinamide to kill actively growing and persistent bacilli and to measure relapse rate. Persistent bacteria were evaluated using Mycobacterium tuberculosis culture supernatant containing resuscitation-promoting factors. Pharmacokinetic parameters and dose-dependent activity for cultivable and persistent bacilli were determined.<h4>Results</h4>Increasing doses of rifampicin in combination with isoniazid and pyrazinamide resulted in dose-dependent faster bacterial clearance. Evaluated both on solid media and in culture filtrate containing resuscitation-promoting factors, a regimen containing a standard dose of rifampicin at 10 mg/kg over 14 weeks failed to achieve organ sterility. In contrast, higher doses of rifampicin achieved organ sterility in a much shorter time of 8-11 weeks. Disease relapse, which occurred in 86% of mice treated with the standard regimen for 14 weeks, was completely prevented by rifampicin doses of ≥ 30 mg/kg.<h4>Conclusions</h4>In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M. tuberculosis, allowing shorter treatment duration without disease relapse.

Item Type: Article
Uncontrolled Keywords: Lung, Spleen, Animals, Mice, Inbred BALB C, Mice, Mycobacterium tuberculosis, Tuberculosis, Disease Models, Animal, Recurrence, Isoniazid, Pyrazinamide, Rifampin, Antitubercular Agents, Drug Therapy, Combination, Dose-Response Relationship, Drug, Female
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Faculty of Science and Engineering > School of Physical Sciences
Depositing User: Symplectic Admin
Date Deposited: 27 Jul 2023 14:18
Last Modified: 13 Feb 2024 14:41
DOI: 10.1093/jac/dkx467
Open Access URL: https://openaccess.sgul.ac.uk/id/eprint/109574/7/R...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3101741